Simposi


Innovation of Mechanism of Action in Oncology

Thursday, October 26th / 15.00-16.00
160 NSCLC updates on ALK inhibitors and 2nd generation immunotherapies clinical data
Federico Cappuzzo
161 NSCLC: Mechanism of Action of ALK inhibitors and 2nd generation Immunotherapies
Romano Danesi